Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacque L Duncan

Showing results (1-10 of 170) with videos related to

Pageof 17
Sort By:
JAMA Ophthalmology|February 3, 2017
Visual Consequences of Delivering Therapies to the Subretinal SpaceJacque L Duncan
NEJM Evidence|July 22, 2025
Ciliary Neurotrophic Factor - A Promising New Therapy for Macular Telangiectasia Type 2Jacque L Duncan
JAMA Ophthalmology|February 8, 2019
Understanding Ocular Inflammation in Eyes Treated With Intravitreal Gene TherapyJacque L Duncan
JAMA Ophthalmology|August 30, 2019
Gene Therapy for Choroideremia-Progress and Remaining QuestionsJacque L Duncan
JAMA Ophthalmology|April 24, 2025
Repeated Low-Level Red Light-More Than Meets the Eye?Jacque L Duncan
JAMA Ophthalmology|February 29, 2024
Retinal End Points for ATXN7-Related Spinocerebellar AtaxiaJacque L Duncan
Ophthalmology|March 27, 2019
Ciliary Neurotrophic Factor Treatment Improves Retinal Structure and Function in Macular Telangiectasia Type 2Jacque L Duncan
Advances in Experimental Medicine and Biology|December 30, 2019
Dysflective ConesJacque L Duncan, Austin Roorda
Developments in Ophthalmology|April 16, 2014
Diagnosis and complementary examinationsMoreno Menghini, Jacque L Duncan
Annual Review of Vision Science|March 15, 2016
Adaptive optics ophthalmoscopyAustin Roorda, Jacque L Duncan
Pageof 17

Showing results (1-10 of 170) with videos related to

Sort By:
Pageof 17
JAMA Ophthalmology|February 3, 2017
Visual Consequences of Delivering Therapies to the Subretinal SpaceJacque L Duncan
NEJM Evidence|July 22, 2025
Ciliary Neurotrophic Factor - A Promising New Therapy for Macular Telangiectasia Type 2Jacque L Duncan
JAMA Ophthalmology|February 8, 2019
Understanding Ocular Inflammation in Eyes Treated With Intravitreal Gene TherapyJacque L Duncan
JAMA Ophthalmology|August 30, 2019
Gene Therapy for Choroideremia-Progress and Remaining QuestionsJacque L Duncan
JAMA Ophthalmology|April 24, 2025
Repeated Low-Level Red Light-More Than Meets the Eye?Jacque L Duncan
JAMA Ophthalmology|February 29, 2024
Retinal End Points for ATXN7-Related Spinocerebellar AtaxiaJacque L Duncan
Ophthalmology|March 27, 2019
Ciliary Neurotrophic Factor Treatment Improves Retinal Structure and Function in Macular Telangiectasia Type 2Jacque L Duncan
Advances in Experimental Medicine and Biology|December 30, 2019
Dysflective ConesJacque L Duncan, Austin Roorda
Developments in Ophthalmology|April 16, 2014
Diagnosis and complementary examinationsMoreno Menghini, Jacque L Duncan
Annual Review of Vision Science|March 15, 2016
Adaptive optics ophthalmoscopyAustin Roorda, Jacque L Duncan
Pageof 17